{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:23:04Z","timestamp":1727497384166},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese Foundation for Hepatitis Prevention and Control grant","award":["YGFK20220066"],"award-info":[{"award-number":["YGFK20220066"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess the immunization efficacy and incidence of adverse reactions after hepatitis B vaccination in children with thalassemia based on data from real-world studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 625 children were recruited into this cross-sectional study. Subgroup analyses of different thalassemia types were performed using binary logistic regression, the factors affecting HBsAb levels were identified using multiple linear regression, and the dose-response relationship between the duration of immunization and seroconversion was explored using the restricted cubic spline (RCS) model to further assess the protective duration of the hepatitis B vaccine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HBsAb positivity in enrolled children was 87.3% in the thalassemia group and 81.4% in the control group. Multifactorial analysis revealed that the duration of immunization, age at completion of vaccination, and whether the first dose was delayed were significant factors influencing HBsAb levels in children (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The threshold for HBsAb positivity may be reached when the immunization duration reaches approximately 30 months. A subgroup analysis revealed that the HBsAb positivity rate was lower in children with \u03b2-thalassemia minor compared to those with \u03b1-thalassemia minor (<jats:italic>P<\/jats:italic>\u2009=\u20090.001, 95% CI: 0.097\u2009\u223c\u20090.536). Adverse reactions after hepatitis B vaccination were dominated by general reactions, with a statistically significant difference in injection-site redness and swelling between the thalassemia and control groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The immunization response to the hepatitis B vaccine in children with thalassemia minor was comparable to healthy children, with no abnormal adverse effects seen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-024-18779-1","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:02:07Z","timestamp":1727438527000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the immunization efficacy and adverse reactions of hepatitis B vaccination in children with thalassemia minor"],"prefix":"10.1186","volume":"24","author":[{"given":"Xue","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jikai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingsong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"10116","key":"18779_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","volume":"391","author":"AT Taher","year":"2018","unstructured":"Taher AT, Weatherall DJ, Cappellini MD, Thalassaemia. Lancet. 2018;391(10116):155\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(17)31822-6.","journal-title":"Lancet"},{"issue":"5","key":"18779_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/jcp.2003.014456","volume":"57","author":"XM Xu","year":"2004","unstructured":"Xu XM, Zhou YQ, Luo GX, et al. The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol. 2004;57(5):517\u201322. https:\/\/doi.org\/10.1136\/jcp.2003.014456.","journal-title":"J Clin Pathol"},{"key":"18779_CR3","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/0264-410X(95)93547-M","volume":"13","author":"M Kane","year":"1995","unstructured":"Kane M. Global Program for control of Hepatitis-B infection. Vaccine. 1995;13:S47\u20139.","journal-title":"Vaccine"},{"issue":"4","key":"18779_CR4","first-page":"516","volume":"49","author":"V Khakhkhar","year":"2006","unstructured":"Khakhkhar V, Joshi PJ. HBsAg seropositivity among multi-transfused thalassemic children. Indian J Pathol Microbiol. 2006;49(4):516\u20138.","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"18779_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5144\/1658-3876.2012.54","volume":"5","author":"AK Mansour","year":"2012","unstructured":"Mansour AK, Aly RM, Abdelrazek SY, et al. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther. 2012;5(1):54\u20139. https:\/\/doi.org\/10.5144\/1658-3876.2012.54.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"18779_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3855\/jidc.1706","volume":"6","author":"O Shaker","year":"2012","unstructured":"Shaker O, Ahmed A, Abdel Satar I, El Ahl H, Shousha W, Doss W. Occult Hepatitis B in Egyptian thalassemic children. J Infect Dev Ctries. 2012;6(4):340\u20136. https:\/\/doi.org\/10.3855\/jidc.1706. Published 2012 Apr 13.","journal-title":"J Infect Dev Ctries"},{"issue":"3","key":"18779_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12098-014-1490-8","volume":"82","author":"J Sabat","year":"2015","unstructured":"Sabat J, Dwibedi B, Dash L, Kar SK. Occult HBV infection in multi transfused thalassemia patients. Indian J Pediatr. 2015;82(3):240\u20134. https:\/\/doi.org\/10.1007\/s12098-014-1490-8.","journal-title":"Indian J Pediatr"},{"issue":"3","key":"18779_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12098-014-1676-0","volume":"82","author":"VP Choudhry","year":"2015","unstructured":"Choudhry VP. Hepatitis B and C infections in multitransfused thalassemic patients. Indian J Pediatr. 2015;82(3):212\u20134. https:\/\/doi.org\/10.1007\/s12098-014-1676-0.","journal-title":"Indian J Pediatr"},{"issue":"1","key":"18779_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/infdis\/168.1.9","volume":"168","author":"HS Margolis","year":"1993","unstructured":"Margolis HS. Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond. J Infect Dis. 1993;168(1):9\u201314. https:\/\/doi.org\/10.1093\/infdis\/168.1.9.","journal-title":"J Infect Dis"},{"issue":"5","key":"18779_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/hep.1840010502","volume":"1","author":"W Szmuness","year":"1981","unstructured":"Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981;1(5):377\u201385. https:\/\/doi.org\/10.1002\/hep.1840010502.","journal-title":"Hepatology"},{"issue":"5","key":"18779_CR11","first-page":"498","volume":"36","author":"GR Sethi","year":"1999","unstructured":"Sethi GR, Sharma S, Sudha S, Rishi RK. Immunogenicity of recombinant hepatitis B vaccine in thalassemic children. Indian Pediatr. 1999;36(5):498\u2013501.","journal-title":"Indian Pediatr"},{"key":"18779_CR12","unstructured":"Eleftheriou Androulla. About Thalassemia. TIF Publication 2003;22\u201334."},{"key":"18779_CR13","doi-asserted-by":"crossref","unstructured":"Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. In: Plotkin SA, Orenstein W, Offit PA, Edwards KM, eds. Plotkin\u2019 s vaccines. 7th Edn. Philadelphia, PA: Elsevier, 2017.","DOI":"10.1016\/B978-0-323-35761-6.00025-0"},{"key":"18779_CR14","doi-asserted-by":"publisher","unstructured":"GBD2020R1VCC. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980\u20132019: a systematic analysis for the global burden of Disease Study 2020, release 1. Lancet. 2021;398(10299):503\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(21)00984-3.","DOI":"10.1016\/S0140-6736(21)00984-3"},{"issue":"12 Suppl 2","key":"18779_CR15","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","volume":"224","author":"J Pattyn","year":"2021","unstructured":"Pattyn J, Hendrickx G, Vorsters A, Van Damme P, Hepatitis B, Vaccines. J Infect Dis. 2021;224(12 Suppl 2):S343\u201351. https:\/\/doi.org\/10.1093\/infdis\/jiaa668.","journal-title":"J Infect Dis"},{"key":"18779_CR16","unstructured":"WHO. World Health Organization. Geneva: 2016. Global health sector strategy on viral hepatitis 2016\u20132021."},{"issue":"3","key":"18779_CR17","doi-asserted-by":"publisher","first-page":"e58029","DOI":"10.1371\/journal.pone.0058029","volume":"8","author":"M Mendy","year":"2013","unstructured":"Mendy M, Peterson I, Hossin S, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS ONE. 2013;8(3):e58029. https:\/\/doi.org\/10.1371\/journal.pone.0058029.","journal-title":"PLoS ONE"},{"issue":"2","key":"18779_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.vaccine.2017.07.046","volume":"37","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017- recommendations. Vaccine. 2019;37(2):223\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.046.","journal-title":"Vaccine"},{"issue":"1","key":"18779_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hep.25988","volume":"57","author":"TW Wu","year":"2013","unstructured":"Wu TW, Lin HH, Wang LY. Chronic hepatitis B infection in adolescents who received primary infantile vaccination. Hepatology. 2013;57(1):37\u201345. https:\/\/doi.org\/10.1002\/hep.25988.","journal-title":"Hepatology"},{"issue":"8957","key":"18779_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/s0140-6736(95)90841-2","volume":"345","author":"R Mangione","year":"1995","unstructured":"Mangione R, Stroffolini T, Tosti ME, Fragapani P, Mele A. Delayed third hepatitis B vaccine dose and immune response. Lancet. 1995;345(8957):1111\u20132. https:\/\/doi.org\/10.1016\/s0140-6736(95)90841-2.","journal-title":"Lancet"},{"key":"18779_CR21","unstructured":"Lu J, Chen J, Ni Z, Huang F, Zhu Y. Effect of delayed vaccination of the 3rd dose on the immune response to hepatitis B vaccine. Chin J Public Health.1997;(02):13."},{"key":"18779_CR22","volume-title":"Implementation of hepatitis B birth dose vaccination\u2014worldwide, 2016","author":"World Health Organization (WHO)","year":"2018","unstructured":"World Health Organization (WHO). Implementation of hepatitis B birth dose vaccination\u2014worldwide, 2016. Geneva, Switzerland: WHO; 2018."},{"issue":"4","key":"18779_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s15010-010-0031-2","volume":"38","author":"S Agladioglu","year":"2010","unstructured":"Agladioglu S, Beyazova U, Camurdan AD, Sahin F, Atak A. Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules. Infection. 2010;38(4):269\u201373. https:\/\/doi.org\/10.1007\/s15010-010-0031-2.","journal-title":"Infection"},{"issue":"5","key":"18779_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/BF01710794","volume":"20","author":"P Dentico","year":"1992","unstructured":"Dentico P, Buongiorno R, Volpe A, Zavoianni A, De Mattia D, Sabato V. Long-term persistence of anti-HBs after hepatitis B immunization in thalassaemic patients. Infection. 1992;20(5):276\u20138. https:\/\/doi.org\/10.1007\/BF01710794.","journal-title":"Infection"},{"issue":"3","key":"18779_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13312-021-2162-1","volume":"58","author":"S Gomber","year":"2021","unstructured":"Gomber S, Yadav R, Dewan P, Ramachandran VG, Puri AS. Requirement of a Booster dose of Hepatitis B Vaccine in Children with Thalassemia after 5 years of primary vaccination: a prospective study. Indian Pediatr. 2021;58(3):237\u201340.","journal-title":"Indian Pediatr"},{"issue":"12","key":"18779_CR26","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1086\/320727","volume":"183","author":"R Cimaz","year":"2001","unstructured":"Cimaz R, Mensi C, D\u2019Angelo E, et al. Safety and immunogenicity of a conjugate vaccine against Haemophilus influenzae type b in splenectomized and nonsplenectomized patients with Cooley anemia. J Infect Dis. 2001;183(12):1819\u201321. https:\/\/doi.org\/10.1086\/320727.","journal-title":"J Infect Dis"},{"issue":"27","key":"18779_CR27","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1016\/j.vaccine.2011.03.080","volume":"29","author":"V Spoulou","year":"2011","unstructured":"Spoulou V, Tzanakaki G, Lekka S, Chouliaras G, Ladis V, Theodoridou M. Natural and vaccine-induced immunity to Neisseria meningitidis serogroup C in asplenic patients with \u03b2-thalassemia. Vaccine. 2011;29(27):4435\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2011.03.080.","journal-title":"Vaccine"},{"issue":"32","key":"18779_CR28","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1016\/j.vaccine.2015.06.100","volume":"33","author":"I Papadatou","year":"2015","unstructured":"Papadatou I, Orthopoulos G, Theodoridou M, Spoulou V. Long-lasting hyporesponsivenss induced by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in asplenic patients with \u03b2-thalassemia major. Vaccine. 2015;33(32):3779\u201383. https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.100.","journal-title":"Vaccine"},{"issue":"3","key":"18779_CR29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00277-019-03615-z","volume":"98","author":"I Papadatou","year":"2019","unstructured":"Papadatou I, Lagousi T, Kattamis A, Spoulou V. Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with \u03b2-thalassemia: assessing the need for booster. Ann Hematol. 2019;98(3):775\u20139. https:\/\/doi.org\/10.1007\/s00277-019-03615-z.","journal-title":"Ann Hematol"},{"issue":"4","key":"18779_CR30","first-page":"339","volume":"80","author":"HL Muncie Jr","year":"2009","unstructured":"Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009;80(4):339\u201344.","journal-title":"Am Fam Physician"},{"issue":"2","key":"18779_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.tmaid.2004.03.009","volume":"2","author":"AJ Zuckerman","year":"2004","unstructured":"Zuckerman AJ. Safety of hepatitis B vaccines. Travel Med Infect Dis. 2004;2(2):81\u20134. https:\/\/doi.org\/10.1016\/j.tmaid.2004.03.009.","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"18779_CR32","first-page":"211","volume":"20","author":"Z Sharifi","year":"2010","unstructured":"Sharifi Z, Milani S, Shooshtari MM. Study on efficacy of Hepatitis B immunization in Vaccinated Beta-Thalassemia Children in Tehran. Iran J Pediatr. 2010;20(2):211\u20135.","journal-title":"Iran J Pediatr"},{"issue":"12","key":"18779_CR33","doi-asserted-by":"publisher","first-page":"929","DOI":"10.19538\/j.ek2018120601","volume":"33","author":"J Fang","year":"2018","unstructured":"Fang J, Yin X, Lan H, et al. Consensus of experts on diagnosis and treatment of non-transfusion dependent thalassemia in children. Chin J Practical Pediatr. 2018;33(12):929\u201334. https:\/\/doi.org\/10.19538\/j.ek2018120601.","journal-title":"Chin J Practical Pediatr"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-18779-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:09:46Z","timestamp":1727438986000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-18779-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["18779"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-18779-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Medical Ethics Review Board of the School of Public Health within Guangdong Pharmaceutical University (Guangzhou, China). The study protocol complied with the Declaration of Helsinki 1964 and its later amendments. All participants\u2019guardians provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are in agreement with the content of the manuscript. All participants\u2019guardians provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2641"}}